A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients with DLBCL
The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.
DLBCL|Lymphoma, B-Cell
DRUG: Polatuzumab vedotin|DRUG: Rituximab|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Prednisone
Progression Free Survival, Measure of time from study enrollment until progression., From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Overall Survival, Measure of time from study enrollment until death from any cause., From date of enrollment until date of death from any cause up to 24 months
In this study, the investigator would like to better understand the efficacy and safety of the addition of polatuzumab vedotin to therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) and dose attenuated R-CHOP in patients who are aged 75 years and older.